Fate Therapeutics Inc
FATE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001434316
In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 2 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $193.2M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Fate Therapeutics Inc changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 249 | 4 | 233 | −12 |
| Shares | 101.1M | 1.13M | 109.5M | +9.53M (+9.5%) |
| Value | $3.92B | $44.0M | $2.70B | −$1.18B (−30.4%) |
4 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (26)
Institutions that held Fate Therapeutics Inc at the end of Q2 2022 but not at the end of Q1 2022.
Sold out (38)
Institutions that held Fate Therapeutics Inc at the end of Q1 2022 and filed for Q2 2022 without it.
Not filed for Q2 2022 yet (4)
Institutions that held Fate Therapeutics Inc at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40.2M |
| Parametric Portfolio Associates LLC | 77,774 | $3.02M |
| Amalgamated Financial Corp. | 13,286 | $515.0K |
| Doheny Asset Management | 5,780 | $224.0K |